Amicus Therapeutics Management
Management criteria checks 4/4
Amicus Therapeutics' CEO is Brad Campbell, appointed in Jan 2015, has a tenure of 9.83 years. total yearly compensation is $8.20M, comprised of 8.5% salary and 91.5% bonuses, including company stock and options. directly owns 0.3% of the company’s shares, worth $8.42M. The average tenure of the management team and the board of directors is 7.7 years and 6.3 years respectively.
Key information
Brad Campbell
Chief executive officer
US$8.2m
Total compensation
| CEO salary percentage | 8.5% |
| CEO tenure | 9.8yrs |
| CEO ownership | 0.3% |
| Management average tenure | 7.7yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden
Nov 10
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
Oct 18'Boring' Amicus Therapeutics Is Making Progress
Sep 29Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector
Aug 16Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues
Jul 02Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt
Jun 06Amicus Therapeutics: Too Cheap At Under $10 A Share
May 20Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough
Mar 27Amicus Therapeutics: Expect Improved Commercial Momentum In 2024
Feb 29Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk
Dec 19Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Jul 06Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors
May 14Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?
Mar 23We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt
Dec 06Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Aug 25Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding
Aug 10Amicus Therapeutics Q2 2022 Earnings Preview
Aug 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$105m |
| Jun 30 2024 | n/a | n/a | -US$120m |
| Mar 31 2024 | n/a | n/a | -US$147m |
| Dec 31 2023 | US$8m | US$699k | -US$152m |
| Sep 30 2023 | n/a | n/a | -US$174m |
| Jun 30 2023 | n/a | n/a | -US$185m |
| Mar 31 2023 | n/a | n/a | -US$204m |
| Dec 31 2022 | US$9m | US$591k | -US$237m |
| Sep 30 2022 | n/a | n/a | -US$264m |
| Jun 30 2022 | n/a | n/a | -US$281m |
| Mar 31 2022 | n/a | n/a | -US$270m |
| Dec 31 2021 | US$5m | US$551k | -US$250m |
| Sep 30 2021 | n/a | n/a | -US$239m |
| Jun 30 2021 | n/a | n/a | -US$252m |
| Mar 31 2021 | n/a | n/a | -US$254m |
| Dec 31 2020 | US$5m | US$516k | -US$277m |
| Sep 30 2020 | n/a | n/a | -US$295m |
| Jun 30 2020 | n/a | n/a | -US$293m |
| Mar 31 2020 | n/a | n/a | -US$325m |
| Dec 31 2019 | US$4m | US$501k | -US$356m |
| Sep 30 2019 | n/a | n/a | -US$345m |
| Jun 30 2019 | n/a | n/a | -US$442m |
| Mar 31 2019 | n/a | n/a | -US$419m |
| Dec 31 2018 | US$3m | US$468k | -US$349m |
| Sep 30 2018 | n/a | n/a | -US$340m |
| Jun 30 2018 | n/a | n/a | -US$293m |
| Mar 31 2018 | n/a | n/a | -US$279m |
| Dec 31 2017 | US$2m | US$450k | -US$284m |
Compensation vs Market: Brad's total compensation ($USD8.20M) is about average for companies of similar size in the US market ($USD6.60M).
Compensation vs Earnings: Brad's compensation has been consistent with company performance over the past year.
CEO
Brad Campbell (48 yo)
9.8yrs
Tenure
US$8,202,366
Compensation
Mr. Bradley L. Campbell, also known as Brad, MBA, serves as Director of Gennao Bio, Inc. since March 2022. He serves as Director of Alliance for Regenerative Medicine. He served as Chief Operating Officer...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 9.8yrs | US$8.20m | 0.30% $ 8.4m | |
| Chief Financial Officer | 1.3yrs | US$3.27m | 0.0048% $ 135.1k | |
| Chief Legal Officer & Corporate Secretary | 8.8yrs | US$4.08m | 0.064% $ 1.8m | |
| Chief People Officer | 6.1yrs | US$3.21m | 0.046% $ 1.3m | |
| Chief Development Officer | no data | US$3.67m | 0.080% $ 2.3m | |
| Chief Accounting Officer & Controller | 6.7yrs | no data | 0.025% $ 702.3k | |
| Chief Science Officer | no data | no data | no data | |
| Senior Director of Investor Relations | no data | no data | no data | |
| Global Chief Compliance & Risk Officer | 9.3yrs | no data | no data | |
| Head of Global Corporate Communications | no data | no data | no data | |
| Chief Patient Advocate | 9.2yrs | no data | no data | |
| Chief Program Officer | 4.5yrs | no data | no data |
7.7yrs
Average Tenure
54.5yo
Average Age
Experienced Management: FOLD's management team is seasoned and experienced (7.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 6.4yrs | US$8.20m | 0.30% $ 8.4m | |
| Independent Director | 5.4yrs | US$391.25k | 0.026% $ 738.6k | |
| Independent Director | 3.9yrs | US$391.25k | 0.0098% $ 279.3k | |
| Independent Director | 18.4yrs | US$407.07k | 0.025% $ 712.5k | |
| Independent Director | 15.1yrs | US$401.25k | 0.017% $ 481.7k | |
| Chairman & Lead Independent Director | 20.8yrs | US$426.25k | 0.025% $ 712.5k | |
| Independent Director | 3.4yrs | US$390.00k | 0.0080% $ 228.5k | |
| Independent Director | 6.2yrs | US$397.50k | 0.024% $ 694.3k |
6.3yrs
Average Tenure
63yo
Average Age
Experienced Board: FOLD's board of directors are considered experienced (6.3 years average tenure).